Helga Schachner

Helga Schachner

Auto-generated profile, based on publicly available information

Helga Schachner

Medical University of Vienna

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2018 in Science
Verified
Journal Article
Closed access
PDF file
MBM. Brown
M. Brown
FAF. P. Assen
F. P. Assen
ALA. Leithner
A. Leithner
JAJ. Abe
J. Abe
HSH. Schachner
H. Schachner
DKD. Kerjaschki
D. Kerjaschki
An alternate route for metastatic cells: Metastatic tumor cells are thought to reach distant organs by traveling through the blood circulation or the lymphatic system. Two studies of mouse models now suggest a hybrid route for tumor cell dissemination. Pereiraet al.and Brownet al.used distinct methodologies to monitor the fate of tumor cells in lymph nodes. They found that tumor cells could invade local blood vessels within a node, exit the node by entering the blood circulation, then go on to colonize the lung. Whether this dissemination route occurs in cancer patients is unknown; the answer could potentially change the way that affected lymph nodes are treated in cancer.Science, this issue p.1403, p.1408

12 April 2018 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
MBMarkus Brown
Markus Brown
LJLouise Johnson
Louise Johnson
DLDario A. Leone
Dario A. Leone
PMPeter Majek
Peter Majek
KVKari Vaahtomeri
Kari Vaahtomeri
DKDontscho Kerjaschki
Dontscho Kerjaschki
Lymphatic endothelial cells (LECs) release extracellular chemokines to guide the migration of dendritic cells. In this study, we report that LECs also release basolateral exosome-rich endothelial vesicles (EEVs) that are secreted in greater numbers in the presence of inflammatory cytokines and accumulate in the perivascular stroma of small lymphatic vessels in human chronic inflammatory diseases. Proteomic analyses of EEV fractions identified >1,700 cargo proteins and revealed a dominant motility-promoting protein signature. In vitro and ex vivo EEV fractions augmented cellular protrusion formation in a CX3CL1/fractalkine-dependent fashion and enhanced the directional migratory response of human dendritic cells along guidance cues. We conclude that perilymphatic LEC exosomes enhance exploratory behavior and thus promote directional migration of CX3CR1-expressing cells in complex tissue environments.

17 March 2021 in Nanomedicine
Verified
Journal Article
Closed access
MGMahlegha Ghavami
Mahlegha Ghavami
CVChrysoula Vraka
Chrysoula Vraka
VHVirginie Hubert
Virginie Hubert
HSHelga Schachner
Helga Schachner
KBKarsten Bamminger
Karsten Bamminger
MMMehdi Frozandeh Moghadam
Mehdi Frozandeh Moghadam
Aim: Here, we established a reliable strategy for generation and characterization of targeted radiolabeled exosomes for the detection of HER2-positive cells quantitatively. Materials & methods: Tar...

1 January 2023
Verified
Conference Paper
Open access
PDF file
CGChristoph A. Gebeshuber
Christoph A. Gebeshuber
LDLisa Daniel-Fischer
Lisa Daniel-Fischer
HRHeinz Regele
Heinz Regele
HSHelga Schachner
Helga Schachner
CAChristoph Aufricht
Christoph Aufricht
PPPaul Perco
Paul Perco
Focal segmental glomerulosclerosis (FSGS) is a glomerular lesion often associated with nephrotic syndrome. It is also associated with a high risk of progression to end-stage kidney disease. Current treatment of FSGS is limited to systemic corticosteroids or calcineurin inhibition, along with inhibitors of the renin-angiotensin-aldosterone system. FSGS is heterogeneous in etiology, and novel therapies targeting specific, dysregulated molecular pathways represent a major unmet medical need. By leveraging big data, we have generated a network-based molecular model of FSGS pathophysiology using previously established systems biology workflows to allow computational evaluation of compounds for their predicted interference with molecular processes contributing to FSGS. We identified repurposing the anti-platelet drug clopidogrel as a therapeutic option to counterbalance dysregulated FSGS pathways. This prediction of our computational screen was validated by testing clopidogrel in the adriamycin FSGS mouse model. Clopidogrel improved key FSGS outcome parameters and significantly reduced urinary albumin to creatinine ratio (p<0.01) and weight loss (p<0.01), and ameliorated histopathological damage (p<0.05). Clopidogrel is used to treat several cardiovascular diseases linked to chronic kidney disease. Clopidogrel's favorable safety profile and its efficacy in the adriamycin mouse FSGS model thus recommend it as an attractive drug repurposing candidate for clinical trial in FSGS. This proof-of-concept study demonstrates the feasibility of translating compounds from our computational technology platform via pre-clinical verification to clinical phase II readiness.

3 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MZMaša Zrimšek
Maša Zrimšek
KDKristina Draganić
Kristina Draganić
AMAnna Malzer
Anna Malzer
VDVerena Doblmayr
Verena Doblmayr
RSRafael de Freitas e Silva
Rafael de Freitas e Silva
Gerda EggerGerda Egger
Gerda Egger
Histone deacetylases (HDACs) play essential roles in T cell development, and several HDAC inhibitors (HDACi) have gained approval for treating peripheral T cell lymphomas. In this study, we investigated the effects of genetic or pharmacological HDAC inhibition on NPM-ALK positive anaplastic large cell lymphoma (ALCL) development to elucidate potential contraindications or indications for the use of HDACi for the treatment of this rare T-cell lymphoma. Short-term systemic pharmacological inhibition of HDACs using the class I-specific HDACi Entinostat in a premalignant ALCL mouse model postponed or even abolished lymphoma development, despite high expression of the NPM-ALK fusion oncogene. To further disentangle the effects of systemic HDAC inhibition from thymocyte intrinsic effects, conditional genetic deletions of highly homologous class I HDAC1 and HDAC2 enzymes were employed. In sharp contrast to the systemic inhibition, T cell-specific deletion of Hdac1 or Hdac2 in the ALCL mouse model significantly accelerated NPM-ALK-driven lymphomagenesis, with Hdac1 loss having a more pronounced effect. Integration of gene expression and chromatin accessibility data revealed that Hdac1 deletion selectively perturbed cell type specific transcriptional programs, crucial for T cell differentiation and signaling. Moreover, multiple oncogenic signaling pathways, including PDGFRB signaling, were highly upregulated. The accelerated lymphomagenesis primarily depended on the catalytic activity of HDAC1, as the expression of a catalytically inactive HDAC1 protein showed similar effects to the complete knockout. Our findings underscore the tumor-suppressive function of class I HDAC1 and HDAC2 in T cells during ALCL development, however systemic pharmacological inhibition of HDACs is still a valid treatment strategy, which could potentially improve current therapeutic outcomes.

29 November 2022 in Kidney360
Verified
Journal Article
Closed access
PDF file
AOAndre Oszwald
Andre Oszwald
RMRaúl A Mejía-Pedroza
Raúl A Mejía-Pedroza
HSHelga Schachner
Helga Schachner
CAChristof Aigner
Christof Aigner
ARAndrew Rees
Andrew Rees
Renate KainRenate Kain
Renate Kain
Introduction: Pauci-immune focal necrotizing glomerulonephritis (piFNGN) involves asynchronous onset and progression of injurious lesions in biopsies. Pathologists describe this heterogeneity within a biopsy, but translating the information into prognostic or expression analyses is challenging. Understanding the underlying molecular processes could improve treatment; however, bulk or single cell transcriptomic analyses of dissociated tissue disregard the heterogeneity of glomerular injury. Methods: We characterize protein and mRNA expression of individual glomeruli in 20 biopsies from 18 patients with anti-neutrophil cytoplasmic antibody-associated piFNGN using the Nanostring digital spatial profiling (DSP) platform. For this purpose, circular annotations of glomeruli were analyzed using protein, immuno-oncology RNA, and cancer transcriptome atlas panels (n=120, 72, and 48 glomeruli, respectively). Histological evaluation of glomerular patterns of injury was performed in adjacent serial sections. Expression data was processed by log2 transformation, quantile normalization and batch adjustment. Results: DSP revealed distinct but overlapping gene expression profiles relating to the morphological evolution of injurious lesions, including dynamic expression of various immune checkpoint regulators. Enrichment analysis indicated deregulated pathways that underline known and highlight novel potential mechanisms of disease. Moreover, by capturing individual glomeruli, DSP describes heterogeneity between and within biopsies. Conclusions: We demonstrate the benefit of spatial profiling for characterization of heterogeneous glomerular injury, indicating novel molecular correlates of glomerular injury in piFNGN. Key Points Pauci-immune focal necrotizing glomerulonephritis (piFNGN) entails heterogeneous glomerular lesions in different stages of evolution. Spatial profiling of glomeruli in piFNGN identifies protein and mRNA signatures that correlate with morphologically distinct lesions. Profiling of individual glomeruli provides insights into pathogenesis of piFNGN, and may identify therapeutic targets or biomarkers.